- Created by Kim Ball, last modified by Anthony DiDonato on Aug 21, 2023
Quick Links
Quality Measures Public Call - August 16, 2023
- Quality Measures Meetings
- Quality Measures - Meeting Processes
- Quality Measures Supporting Materials
- Discovery Use Case Concepts (Phase 0)
- Architecture
- Quality Measures - Use Case Development Guidelines Checklist
- Quality Measures Glossary
Please refer to Quality Measures - Proposal for additional use case details
mCODE Implementation Guide (STU 2)
Project Overview
Problem:
- Digital oncology measure development/authoring has been constrained by an ecosystem of disparate and unstructured data, as well as a lack of digitalized collections and oncology models to support interoperability.
- Consequently, the majority of oncology quality measures data collection has required manual abstraction resulting in significant burden, and an overall lack of opportunity to share this unstandardized information across systems or organizations.
Description:
Target Outcome:
- Create a solution that demonstrates the ability to author and evaluate digital measures using FHIR data model with mCODE profile extensions and data elements for value-based programs and clinical quality improvement in the Oncology domain.
- This use case will focus on the beginning of a measure’s life cycle and start with quality measure authoring.
- Initial project scope will focus efforts to:
- Author and develop a process for setting up necessary data elements in discrete data fields, to be used for data collection and aggregation.
- Prove that measures can be authored and executed using mCODE, and FHIR, and the correct measure result can be obtained.
- This use case will start with the authoring and development of test case bundles using a single measure initially for phase 0.
Value:
Overall, the intent of the Quality Measures use case is to highlight new quality measures that could be developed – and new insights that could be made – if mCODE and other FHIR IGs (such as QI Core) were implemented and leveraged by an ecosystem of willing health organizations. This is the value of using the ASTRO/VA radiotherapy measures: they can be an exemplar showing what can be achieved, by leveraging mCODE and the Radiation Therapy IG, to create and hopefully roll out new/innovative quality measures in clinical practice.
Additionally:
- The clinical oncology subject matter expertise of the CodeX community, paired with the mCODE profiles and FHIR IGs, should allow for the authoring of these quality metrics and provide a proof of concept for measure developers
- Specifically, there is significant value in demonstrating that quality measure authoring of oncology measures will be easier and more feasible using a FHIR- (and mCODE)-based solution.
- With the expansion of programs focusing on collection of meaningful oncology quality measure data, such as the VA initiatives, the Advancing Cancer Care MVP (MIPS), in support of the Federal Cancer Moonshot Initiative, and the Enhancing Oncology Model (EOM), this CodeX use case team wishes to provide solutions using HL7 FHIR and mCODE to provide a path to data collection with reduced burden.
Project Plan
Phase | Milestone | Timeline |
---|---|---|
Discovery | Use case identification | COMPLETE |
Planning | Plan out high level project plan, deliverables, success measures, high level timeline, key stakeholders, etc | COMPLETE |
Phase 0 | Using Telligen Quality Measures Engine (QME) Tooling, as a proof of concept, to determine if digitalized measures using FHIR and mCODE are feasible and functional. The team started with:
Process:
Results:
| COMPLETE Recpt ser |
Phase 1 | Expand portfolio of VA quality measures and repeat measure mapping, authoring, test bundle creation and testing steps Current Measures include:
| ON TRACK |
Phase 2 | Expand portfolio by aligning to oncology quality measures in federal models and among oncology steward programs
In addition to aligning to federal models, longer-term VA measures include:
| TBD |
Phase 3 | Source real world Clinical Data Repository endpoints for measure data source | TBD |
Conference Call Information
Public Call meetings are ad-hoc, based on project updates
Use Case Team
Name | Affiliation | Role |
---|---|---|
Randi Kudner | ASTRO | Champion / Primary Point of Contact |
Samantha Dawes | ASTRO | Champion |
Charlotte Raley | ASTRO | ASTRO measures and RT Support |
Stephanie Jones | ASCO | Champion / Primary Point of Contact |
Caitlin Drumheller | ASCO | ASCO Measure SME |
Yvette Apura | ASCO | Clinical Informaticist / ASCO Measure SME |
Becky Metzger | Telligen | Champion / Primary Point of Contact |
Gail Winters | Telligen | Technical SME |
Sharon Labbate | Telligen | Technical / Terminology SME |
Jessica Pugh | Telligen | Project Management for Telligen-focused tasks |
Dennis Blair | Evernorth | Champion / Primary Point of Contact |
Rick Emery | Evernorth | Champion |
Dr. Mary Kay Barton | Evernorth | Medical Oncology SME |
Dr. Vik Shah | Evernorth | Medical Oncology SME / Cigna Representative |
Dr. Nimi Tuamokumo | Evernorth | Radiation Oncology SME |
Sondra Berger | Evernorth | Business Development |
Sharon Sebastian | MITRE | Clinical Informaticist / Terminology Support |
Rob Dingwell | MITRE | Technical Support |
Anthony DiDonato | MITRE | Project co-Coordinator |
Doug Williams | CentanniPark | Project co-Coordinator |
If you'd like to learn more about this use case, please contact Anthony DiDonato - adidonato@mitre.org
Current Collaborators
- American Society of Clinical Oncology
- American Society for Radiation Oncology
- Cigna/Evernorth
- MITRE
- Telligen
- Centanni Park
- No labels